Bio-Thera Solutions Initiates Phase I Clinical Trial for BAT2506, a Proposed Biosimilar of Simponi® (Golimumab)
(WorldNews Business)

GUANGZHOU, China--(BUSINESS WIRE)--Aug 14, 2019-- Bio-Thera Solutions, a clinical-stage pharmaceutical company, today announced that dosing has begun in a Phase I clinical study to compare the pharmacokinetics and safety of BAT2506, a proposed biosimilar of Simponi ® (golimumab), to EU-sourced Simponi ® in normal healthy volunteers. The clinical study is a randomized, double-blind, two-arm, parallel group study that is expected to enroll approximately 182 healthy volunteers. Each patient will receive a single...